ClinicalTrials.gg
RecruitingNCT06914128Updated Nov 12, 2026

A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

A Phase 1/2 interventional study of BAY 3713372 in MTAP-deleted Solid Tumors, sponsored by Bayer. Recruiting at 62 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Bayer · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Nov 12, 2026Site recruiting status changed25 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
450
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Carcinoma, Non-Small-Cell Lung by Bayer — 3 open to participants now, 5 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · Bayer.

Planned enrollment
4th of 28
450 · median 85
Started
2025
the only one that year
Phase 1/2
2 of 28
2 open now
Registered
28th of 28
by date

Among the 28 studies in Carcinoma, Non-Small-Cell Lung by Bayer, this one is the 4th largest by planned enrollment, is the only one that started in 2025, is one of 2 in phase 1/2, and was the 28th registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

3 of the 28 studies in Carcinoma, Non-Small-Cell Lung by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Carcinoma, Non-Small-Cell Lung by Bayer, or all of them as a file.
02

Study summary

The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells.

The main objective of this first-in-human study is to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with MTAP-deleted solid tumors.

For this, the researchers will study and analyze:

  • the number of participants who have adverse events (AEs) after receiving different doses of BAY 3713372 and the AE's severity.
  • the number of participants who experience dose-limiting toxicities (DLTs) after receiving different doses of BAY 3713372, the DLT's severity and how often they happened. A DLT is a pre-defined medical problem caused by a specific dose of a drug that is too severe to continue using that dose.
  • the total amount of BAY 3713372 in participants' blood (also called AUC) over time after single and multiple doses.
  • the highest level of BAY 3713372 in participants' blood (also called Cmax) after single and multiple doses.

Other than the main objective, researchers will also check for the number of participants who show a response to treatment and how long they live without the cancer getting worse.

The study participants will take part in one of the eight distinct groups or "intervention cohorts" of the study. The study will start with a dose escalation phase where distinct groups of participants will receive different doses of BAY 3713372 alone to find the dose that is deemed safe and works best for the participants. When this dose has been found, a larger number of participants will receive BAY 3713372 alone or with other treatments in a dose expansion phase.

Participants may take the study treatment as long as they benefit from the treatment without any severe medical problems.

Participants will visit the study site:

  • at least twice before the treatment starts
  • multiple times when they start taking the treatment
  • once after 30 days of receiving the last dose and every 9 weeks after that until the cancer worsens, or the participant stops for any other reason

During the study, the doctors and their study team will:

  • check participants' health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram
  • check if the participants' cancer has grown and/or spread using computed tomography (CT) or magnetic resonance imaging (MRI) and, if needed, bone scan
  • take tumor samples

The study doctors and their team will contact the participants every 3 months until 2 years after the last participant's last dose or the end of the study to learn about the participant's health.

03

Conditions studied

  • MTAP-deleted Solid Tumors

Keywords

  • Solid Tumors
  • Non-small cell lung cancer
  • NSCLC
  • Pancreatic adenocarcinoma
  • PDAC
  • Glioblastoma
  • GBM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 18 years old of age, or the legal age of consent in the jurisdiction of the country in which the study takes place, at the time of signing the .
  • At least one that would qualify as target lesion by , Version 1.1 (RECIST 1.1).
  • Homozygous MTAP-deletion identified through molecular testing from a locally certified laboratory.
  • (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Previous additional cancer other than the one evaluated in this study within the past 2 years except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder tumors, localized prostate cancer or other tumors that in the opinion of the investigator, are considered cured or not immediately life-threatening, and will not interfere with the scientific goals of this study.
  • A marked prolongation of /QTc interval at screening (e.g., repeated demonstration of a QTc interval >450 ms). Participants with permanent pacemakers (i.e., a paced rhythm) may be eligible based on the investigator's clinical assessment and discretion.
  • Cardiac history comprising:

    • History of congestive heart failure Class >II according to the Functional Classification.
    • Myocardial infarction less than 6 months before the start of study intervention.
    • Serious cardiac arrhythmias requiring treatment or any abnormalities in rhythm, conduction or morphology on resting with the exception of atrial fibrillation which is well-controlled and requires only digoxin or beta blockers.
  • Unstable angina within 4 weeks before start of study intervention.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • Experimental
    Dose Escalation (Intervention Cohort 1)

    For the escalation part, different dose levels of BAY 3713372 administered as monotherapy are planned.

    Drug: BAY 3713372

  • Experimental
    Backfill cohorts in Intervention Cohort 1 (Dose Escalation)

    Backfill cohorts may be initiated concurrently with dose escalation cohorts to generate additional safety, pharmacokinetic, and pharmacodynamic data to facilitate the selection of the optimal doses for use in further development.

    Drug: BAY 3713372

  • Experimental
    Dose Expansion (Intervention Cohort 1)

    Dose expansion with BAY 3713372 monotherapy in selected participants with MTAP-deleted solid tumors.

    Drug: BAY 3713372

  • Experimental
    Dose Expansion (Intervention Cohort 2)

    Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted non-small cell lung cancer (NSCLC).

    Drug: BAY 3713372

  • Experimental
    Dose Expansion (Intervention Cohort 3)

    Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted NSCLC.

    Drug: BAY 3713372

  • Experimental
    Dose Expansion (Intervention Cohort 4)

    Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted NSCLC.

    Drug: BAY 3713372

  • Experimental
    Dose Expansion (Intervention Cohort 5)

    Dose expansion with BAY 3713372 monotherapy in participants with MTAP-deleted pancreatic ductal adenocarcinoma (PDAC).

    Drug: BAY 3713372

  • Experimental
    Dose Expansion (Intervention Cohort 6)

    Dose expansion with BAY 3713372 in combination with other treatments in participants with MTAP-deleted PDAC.

    Drug: BAY 3713372

  • Experimental
    Window-of-opportunity trial in participants with MTAP-deleted GBM (Intervention Cohort 7)

    A surgical window-of-opportunity trial of BAY 3713372 alone in participants with MTAP-deleted glioblastoma (GBM).

    Drug: BAY 3713372

Interventions

  • DrugBAY 3713372

    Daily oral administration

06

What researchers measure

Primary outcomes

  1. Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent adverse events (TEAEs)

    TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

    Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention

  2. Dose Escalation (Master and Intervention Cohort 1): Number of participants with treatment-emergent serious adverse events (TESAEs)

    TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

    Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention

  3. Dose Escalation (Master and Intervention Cohort 1): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)

    TEAEs and TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

    Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention

  4. Dose Escalation (Master and Intervention Cohort 1): Incidence of dose-limiting toxicities (DLTs)

    DLTs per participants. DLTs will be graded according to NCI-CTCAE v.5.0

    Time frame: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)

  5. Dose Escalation (Master and Intervention Cohort 1): Number of participants with DLTs

    Number of participants with at least one DLT

    Time frame: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)

  6. Dose Escalation (Master and Intervention Cohort 1): Maximum concentration (Cmax) of the respective dosing interval of BAY 3713372

    Time frame: From the first dose of study intervention up to Cycle 2 Day 1 (each cycle is 21 days)

  7. Dose Escalation (Master and Intervention Cohort 1): Area under the curve (AUC) of the respective dosing interval of BAY 3713372

    Time frame: From the first dose of study intervention up to Cycle 2 Day 1 (each cycle is 21 days)

  8. Dose Expansion (Master, Intervention Cohorts 1 - 6): Objective response rate (ORR)

    Determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

    Time frame: Approximately 1.5 years

  9. Dose Expansion (Intervention Cohorts 3, 4 and 6): Number of participants with DLTs

    Number of participants with at least one DLT

    Time frame: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)

  10. Intervention Cohort 7: Number of participants with treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)

    TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

    Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention

  11. Intervention Cohort 7: Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)

    TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

    Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention

  12. Intervention Cohort 7: Number of participants with DLTs

    Number of participants with at least one DLT

    Time frame: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days)

  13. Intervention Cohort 7: Brain and brain tumor PK concentration of BAY 3713372

    Concentration of BAY 3713372 in enhancing and non-enhancing brain tumor tissue obtained at definitive surgery, with corresponding time-matched plasma concentrations and estimation of tumor-to-plasma exposure ratios

    Time frame: From first dose through day of surgery (approximately 7 ± 2 days)

  14. Intervention Cohort 7: Tumor tissue SDMA levels

    Change in symmetric dimethylarginine (SDMA) levels in brain tumor tissue collected at definitive surgery following neoadjuvant BAY 3713372 treatment, as a pharmacodynamic marker of PRMT5 inhibition

    Time frame: From first dose through day of surgery (approximately 7 ± 2 days)

Secondary outcomes

  1. Dose Escalation (Master and Intervention Cohort 1): Objective response rate (ORR)

    Determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)

    Time frame: Approximately 1.5 years

  2. Dose Escalation (Master and Intervention Cohort 1): Duration of response (DOR)

    Determined by the investigator according to RECIST v1.1

    Time frame: Approximately 3 years

  3. Dose Escalation (Master and Intervention Cohort 1): Progression-free survival (PFS)

    Determined by the investigator according to RECIST v1.1

    Time frame: Approximately 3 years

  4. Dose Escalation (Master and Intervention Cohort 1): Time to response (TTR)

    Time frame: Approximately 1.5 years

  5. Dose Expansion (Master, Intervention Cohorts 1 - 6): Number of participants with treatment-emergent adverse events (TEAEs)

    TEAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

    Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention

  6. Dose Expansion (Master, Intervention Cohorts 1 - 6): Number of participants with treatment-emergent serious adverse events (TESAEs)

    TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

    Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention

  7. Dose Expansion (Master, Intervention Cohorts 1 - 6): Severity of treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs)

    TEAEs and TESAEs will be graded according to NCI-CTCAE v.5.0 and will be reported using the latest version of MedDRA coding dictionary

    Time frame: From the first administration of study intervention up to 30 days after the last dose of study intervention

  8. Dose Expansion (Master, Intervention Cohorts 1, 3, 4, and 6): Incidence of dose-limiting toxicities (DLTs)

    DLTs per participants. DLTs will be graded according to NCI-CTCAE v.5.0

    Time frame: From the first dose of study intervention to the end of Cycle 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)

  9. Dose Expansion (Master, Intervention Cohorts 1 - 6): Duration of response (DOR)

    Determined by the investigator according to RECIST v1.1

    Time frame: Approximately 3 years

  10. Dose Expansion (Master, Intervention Cohorts 1 - 6): Progression-free survival (PFS)

    Determined by the investigator according to RECIST v1.1

    Time frame: Approximately 3 years

  11. Dose Expansion (Master, Intervention Cohorts 1 - 6): Time to response (TTR)

    Time frame: Approximately 1.5 years

  12. Dose Expansion (Master, Intervention Cohorts 1 - 4, and 6): Maximum concentration (Cmax) of the respective dosing interval of BAY 3713372

    Time frame: From the first dose of study intervention up to Cycle 2 Day 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)

  13. Dose Expansion (Master, Intervention Cohorts 1 - 4, and 6): Area under the curve (AUC) of the respective dosing interval of BAY 3713372

    Time frame: From the first dose of study intervention up to Cycle 2 Day 1 (each cycle is 21 days, except for Intervention Cohort 6, which has a cycle length of 28 days)

  14. Dose Expansion (Part A of Intenvention Cohort 2): Time to CNS progression (CNS-TTP)

    Time frame: Approximately 3 years

  15. Dose Expansion (Part B of Intervention Cohort 2): CNS-ORR for active brain metastases

    CNS-ORR: CNS objective response rate

    Time frame: Approximately 1.5 years

  16. Dose Expansion (Part B of Intervention Cohort 2): CNS-DOR for active brain metastases

    CNS-DOR: Duration of CNS response

    Time frame: Approximately 3 years

  17. Dose Expansion (Part B of Intervention Cohort 2): CNS-PFS for active brain metastases

    CNS-PFS: Survival without CNS progression

    Time frame: Approximately 3 years

  18. Dose Expansion (Part B of Intervention Cohort 2): CNS-TTR for active brain metastases

    CNS-TTR: Time to CNS response

    Time frame: Approximately 1.5 years

  19. Dose Expansion (Part B of Intervention Cohort 2): CNS-related disease control rate (CNS-DCR) in active brain metastases

    Time frame: Approximately 1.5 years

07

Study locations

45 of 62 sites recruiting
  • UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital
    Birmingham, Alabama 35233, United States
    Not yet recruiting
  • City of Hope - Duarte Cancer Center
    Duarte, California 91010, United States
    Not yet recruiting
  • UCLA Health Bowyer Oncology Center
    Los Angeles, California 90095, United States
    Not yet recruiting
  • UCSF Helen Diller Medical Center at Parnassus Heights - Neurology
    San Francisco, California 94143, United States
    Recruiting
  • Stanford University Medical Center - Neurology
    Stanford, California 94305, United States
    Not yet recruiting
  • UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center
    Aurora, Colorado 80045, United States
    Not yet recruiting
  • Sarah Cannon Research Institute at HCA HealthONE Presbyterian St. Luke's
    Denver, Colorado 80218, United States
    Recruiting
  • Sarah Cannon Research Institute at Florida Cancer Specialists- Lake Nona
    Orlando, Florida 32827, United States
    Recruiting
  • Massachusetts General Hospital - Neurology
    Boston, Massachusetts 02114, United States
    Recruiting
  • Dana-Farber Cancer Institute - Oncology Department
    Boston, Massachusetts 02215, United States
    Not yet recruiting
  • START | Midwest
    Grand Rapids, Michigan 49546, United States
    Recruiting
  • Icahn School of Medicine at Mount Sinai - Oncology
    New York, New York 10029, United States
    Recruiting
  • Memorial Sloan Kettering Cancer Center New York - Main Campus
    New York, New York 10065, United States
    Recruiting
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
  • NEXT Dallas - Oncology Department
    Irving, Texas 75039, United States
    Recruiting
  • START | San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
  • Froedtert Hospital - Clinical Cancer Center
    Milwaukee, Wisconsin 53226, United States
    Not yet recruiting
  • Chris O'Brien Lifehouse
    Camperdown, New South Wales 2050, Australia
    Recruiting
  • Concord Repatriation General Hospital (CRGH) (Concord Hospital) - Concord Cancer Centre
    Concord, New South Wales 2139, Australia
    Recruiting
  • Northern Hospital
    Epping, New South Wales 3076, Australia
    Not yet recruiting
  • Calvary Mater Hospital Newcastle - Oncology
    Waratah, New South Wales 2298, Australia
    Recruiting
  • Antwerp University Hospital | Oncology Department
    Antwerp, Antwerp 2650, Belgium
    Recruiting
  • Ghent University Hospital | Drug Research Unit Department
    Ghent, East Flanders 9000, Belgium
    Recruiting
  • UZ Leuven Gasthuisberg - Pneumology Department
    Leuven, Flemish Brabant 3000, Belgium
    Recruiting
  • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology
    Liège, Liège 4000, Belgium
    Recruiting
  • Beijing Cancer Hospital - Oncology Department
    Beijing, Beijing Municipality 100142, China
    Recruiting
  • Beijing chest hospital, Capital Medical University
    Beijing, Beijing Municipality 101149, China
    Not yet recruiting
  • Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.
    Wuhan, Hubei 430075, China
    Recruiting
  • Jiangsu Provincial People's Hospital - The First Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210029, China
    Not yet recruiting
  • Sir Run Run Shaw Hospital, Zhejiang Univ. School of Medicine - Oncology Department
    Hangzhou, Zhejiang 310016, China
    Not yet recruiting
  • Fakultní nemocnice Olomouc - Onkologická klinika
    Olomouc, Olomouc Region 779 00, Czechia
    Recruiting
  • Masarykova Univerzita - Masarykuv Onkologicky Ustav (MOU) - Klinika Komplexni Onkologicke Pece (KKOP)
    Brno, South Moravian 602 00, Czechia
    Recruiting
  • Rigshospitalet Copenhagen University Hospital | Oncology Department
    Copenhagen, Capital Region / Region Hovedstaden 2100, Denmark
    Recruiting
  • Odense University Hospital | Svendborg Sygehus - Oncology Department
    Odense, Region of Southern Denmark / Region Syddanmark 5000, Denmark
    Recruiting
  • Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati
    Aviano, Friuli Venezia Giulia 33081, Italy
    Recruiting
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I
    Rome, Lazio 00128, Italy
    Recruiting
  • I.F.O. Istituti Fisioterapici Ospitalieri - Sperimentazioni cliniche Fase 1 e Medicina di precisione
    Rome, Lazio 00144, Italy
    Not yet recruiting
  • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1
    Milan, Lombardy 20133, Italy
    Recruiting
  • Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia
    Rozzano, Lombardy 20089, Italy
    Recruiting
  • Nagoya University Hospital
    Nagoya, Aichi-ken 466-8560, Japan
    Not yet recruiting
  • Kindai University Hospital
    Sakai, Osaka 590-0197, Japan
    Recruiting
  • Shizuoka Cancer Center
    Sunto, Shizuoka 411-8777, Japan
    Recruiting
  • National Cancer Center Hospital
    Chuo-ku, Tokyo 104-0045, Japan
    Recruiting
  • The Cancer Institute Hospital of JFCR
    Koto-ku, Tokyo 135-8550, Japan
    Recruiting
  • Nederlands Kanker Instituut
    Amsterdam, North Holland 1066 CX, Netherlands
    Recruiting
  • Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center
    Groningen, Provincie Groningen 9713 GZ, Netherlands
    Not yet recruiting
  • Erasmus Medisch Centrum
    Rotterdam, South Holland 3015 CE, Netherlands
    Recruiting
  • National University Hospital Medical Centre
    Singapore, Singapore 119074, Singapore
    Recruiting
  • National Cancer Center Singapore - Oncology Department
    Singapore, Singapore 168583, Singapore
    Recruiting
  • Icon Cancer Centre
    Singapore, Singapore 217562, Singapore
    Recruiting
  • Hospital Hm Nou Delfos | Oncologia
    Barcelona, Barcelona 08023, Spain
    Recruiting
  • Hospital Universitari Vall D Hebron | Oncologia
    Barcelona, Barcelona 08035, Spain
    Recruiting
  • Clinica Universidad De Navarra | Pamplona | Oncologia
    Pamplona, Chartered Community of Navarre 31008, Spain
    Recruiting
  • Hospital San Pedro | Oncologia
    Logroño, La Rioja 26006, Spain
    Recruiting
  • Hospital Universitario Fundacion Jimenez Diaz | Oncologia
    Madrid, Madrid 28040, Spain
    Recruiting
  • NEXT - Hospital Universitario Quironsalud Madrid | Oncologia
    Pozuelo de Alarcón, Madrid 28223, Spain
    Recruiting
  • Hospital Universitario Virgen De La Victoria | Oncologia
    Málaga, Málaga 29010, Spain
    Recruiting
  • Hospital Clinico Universitario De Valencia | Oncologia
    Valencia, Valencia 46010, Spain
    Not yet recruiting
  • Karolinska Universitetssjukhuset - Solna - Fas I-enheten Solna CKC
    Stockholm, Stockholm County 171 76, Sweden
    Recruiting
  • Sahlgrenska Universitetssjukhuset - Sahlgrenska Sjukhuset - Klinisk prövningsenhet Fas I/FIH
    Gothenburg, Västra Götaland County 413 46, Sweden
    Not yet recruiting
  • The Christie Hospital | Experimental Cancer Medicine Team
    Manchester, Greater Manchester M20 4BX, United Kingdom
    Recruiting
  • The Royal Marsden (Surrey) | Oak Foundation Drug Development Unit
    Sutton, Surrey SM2 5PT, United Kingdom
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jun 2029, 50 months after the start.

Of 311 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 50 months is below that.

Counting every sponsor, half of 434 studies reached it within 62 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
Apr 6, 2025
StartActual
Mar 21, 2025
Primary completionEst.
Jun 18, 2029
CompletionEst.
Jun 18, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
25 sites added, 26 sites removed. 8 sites changed recruiting status (4 now recruiting, 4 now not yet recruiting)
Show 8 sites
  • UCSF Helen Diller Medical Center at Parnassus Heights - Neurology · San Francisco, United StatesNot yet recruiting→Recruiting
  • Dana-Farber Cancer Institute - Oncology Department · Boston, United StatesRecruiting→Not yet recruiting
  • Icahn School of Medicine at Mount Sinai - Oncology · New York, United StatesNot yet recruiting→Recruiting
  • Froedtert Hospital - Clinical Cancer Center · Milwaukee, United StatesRecruiting→Not yet recruiting
  • UZ Leuven Gasthuisberg - Pneumology Department · Leuven, BelgiumNot yet recruiting→Recruiting
  • Nagoya University Hospital · Nagoya, JapanRecruiting→Not yet recruiting
  • Erasmus Medisch Centrum · Rotterdam, NetherlandsNot yet recruiting→Recruiting
  • Sahlgrenska Universitetssjukhuset - Sahlgrenska Sjukhuset - Klinisk prövningsenhet Fas I/FIH · Gothenburg, SwedenRecruiting→Not yet recruiting
Show 25 added (12 Spain, 5 Italy, 3 Singapore, 2 Belgium, 2 Netherlands, 1 United Kingdom)
  • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology · Liège, Belgium
  • Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati · Aviano, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I · Rome, Italy
  • I.F.O. Istituti Fisioterapici Ospitalieri - Sperimentazioni cliniche Fase 1 e Medicina di precisione · Rome, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1 · Milan, Italy
  • Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia · Rozzano, Italy
  • Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center · Groningen, Netherlands
  • Clinica Universidad De Navarra | Pamplona | Oncologia · Pamplona, Spain
  • Hospital Hm Nou Delfos | Oncologia · Barcelona, Spain
  • Hospital Universitari Vall D Hebron | Oncologia · Barcelona, Spain
  • Hospital Universitario Fundacion Jimenez Diaz | Oncologia · Madrid, Spain
  • Hospital Universitario Virgen De La Victoria | Oncologia · Málaga, Spain
  • Hospital Clinico Universitario De Valencia | Oncologia · Valencia, Spain
  • The Royal Marsden (Surrey) | Oak Foundation Drug Development Unit · Sutton, United Kingdom
  • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology · Liège, Belgium
  • Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center · Groningen, Netherlands
  • National University Hospital Medical Centre · Singapore, Singapore
  • National Cancer Center Singapore - Oncology Department · Singapore, Singapore
  • Icon Cancer Centre · Singapore, Singapore
  • Hospital Hm Nou Delfos | Oncologia · Barcelona, Spain
  • Hospital Universitari Vall D Hebron | Oncologia · Barcelona, Spain
  • Clinica Universidad De Navarra | Pamplona | Oncologia · Pamplona, Spain
  • Hospital Universitario Fundacion Jimenez Diaz | Oncologia · Madrid, Spain
  • Hospital Universitario Virgen De La Victoria | Oncologia · Málaga, Spain
  • Hospital Clinico Universitario De Valencia | Oncologia · Valencia, Spain
Show 26 removed
  • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology · Liège, Belgium
  • Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati · Aviano, Italy
  • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1 · Milan, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I · Roma, Italy
  • I.F.O. Istituti Fisioterapici Ospitalieri - Sperimentazioni cliniche Fase 1 e Medicina di precisione · Roma, Italy
  • Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia · Rozzano, Italy
  • Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center · Groningen, Netherlands
  • Hospital Hm Nou Delfos | Oncologia · Barcelona, Spain
  • Hospital Universitari Vall D Hebron | Oncologia · Barcelona, Spain
  • Hospital Universitario Fundacion Jimenez Diaz | Oncologia · Madrid, Spain
  • Hospital Universitario Virgen De La Victoria | Oncologia · Málaga, Spain
  • Hospital Clinico Universitario De Valencia | Oncologia · Valencia, Spain
  • Clinica Universidad De Navarra | Pamplona | Oncologia · Pamplona, Spain
  • The Royal Marsden Hospital (Sutton, Surrey) | Oak Foundation Drug Development Unit · Sutton, United Kingdom
  • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology · Liège, Belgium
  • National Cancer Center Hospital East · Kashiwa, Japan
  • Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center · Groningen, Netherlands
  • National University Hospital Medical Centre · Singapore, Singapore
  • National Cancer Center Singapore - Oncology Department · Singapore, Singapore
  • Icon Cancer Centre · Singapore, Singapore
  • Clinica Universidad De Navarra | Pamplona | Oncologia · Pamplona, Spain
  • Hospital Hm Nou Delfos | Oncologia · Barcelona, Spain
  • Hospital Universitari Vall D Hebron | Oncologia · Barcelona, Spain
  • Hospital Universitario Fundacion Jimenez Diaz | Oncologia · Madrid, Spain
  • Hospital Universitario Virgen De La Victoria | Oncologia · Málaga, Spain
  • Hospital Clinico Universitario De Valencia | Oncologia · Valencia, Spain
across 2 updates, Oct 27, 2026 – Nov 12, 2026
Show all 3 updates
  1. Nov 12, 2026
    11 sites added, 12 sites removed
    Show 11 added (6 Spain, 3 Singapore, 1 Belgium, 1 Netherlands)
    • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology · Liège, Belgium
    • Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center · Groningen, Netherlands
    • National University Hospital Medical Centre · Singapore, Singapore
    • National Cancer Center Singapore - Oncology Department · Singapore, Singapore
    • Icon Cancer Centre · Singapore, Singapore
    • Hospital Hm Nou Delfos | Oncologia · Barcelona, Spain
    • Hospital Universitari Vall D Hebron | Oncologia · Barcelona, Spain
    • Clinica Universidad De Navarra | Pamplona | Oncologia · Pamplona, Spain
    • Hospital Universitario Fundacion Jimenez Diaz | Oncologia · Madrid, Spain
    • Hospital Universitario Virgen De La Victoria | Oncologia · Málaga, Spain
    • Hospital Clinico Universitario De Valencia | Oncologia · Valencia, Spain
    Show 12 removed
    • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology · Liège, Belgium
    • National Cancer Center Hospital East · Kashiwa, Japan
    • Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center · Groningen, Netherlands
    • National University Hospital Medical Centre · Singapore, Singapore
    • National Cancer Center Singapore - Oncology Department · Singapore, Singapore
    • Icon Cancer Centre · Singapore, Singapore
    • Clinica Universidad De Navarra | Pamplona | Oncologia · Pamplona, Spain
    • Hospital Hm Nou Delfos | Oncologia · Barcelona, Spain
    • Hospital Universitari Vall D Hebron | Oncologia · Barcelona, Spain
    • Hospital Universitario Fundacion Jimenez Diaz | Oncologia · Madrid, Spain
    • Hospital Universitario Virgen De La Victoria | Oncologia · Málaga, Spain
    • Hospital Clinico Universitario De Valencia | Oncologia · Valencia, Spain
    + 1 other change: verification date
  2. Oct 28, 2026
    Minor edits only
    + 1 other change: verification date
  3. Oct 27, 2026
    14 sites added, 14 sites removed. 8 sites changed recruiting status (4 now recruiting, 4 now not yet recruiting)
    Show 8 sites
    • UCSF Helen Diller Medical Center at Parnassus Heights - Neurology · San Francisco, United StatesNot yet recruiting→Recruiting
    • Dana-Farber Cancer Institute - Oncology Department · Boston, United StatesRecruiting→Not yet recruiting
    • Icahn School of Medicine at Mount Sinai - Oncology · New York, United StatesNot yet recruiting→Recruiting
    • Froedtert Hospital - Clinical Cancer Center · Milwaukee, United StatesRecruiting→Not yet recruiting
    • UZ Leuven Gasthuisberg - Pneumology Department · Leuven, BelgiumNot yet recruiting→Recruiting
    • Nagoya University Hospital · Nagoya, JapanRecruiting→Not yet recruiting
    • Erasmus Medisch Centrum · Rotterdam, NetherlandsNot yet recruiting→Recruiting
    • Sahlgrenska Universitetssjukhuset - Sahlgrenska Sjukhuset - Klinisk prövningsenhet Fas I/FIH · Gothenburg, SwedenRecruiting→Not yet recruiting
    Show 14 added (6 Spain, 5 Italy, 1 Belgium, 1 Netherlands, 1 United Kingdom)
    • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology · Liège, Belgium
    • Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati · Aviano, Italy
    • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I · Rome, Italy
    • I.F.O. Istituti Fisioterapici Ospitalieri - Sperimentazioni cliniche Fase 1 e Medicina di precisione · Rome, Italy
    • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1 · Milan, Italy
    • Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia · Rozzano, Italy
    • Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center · Groningen, Netherlands
    • Clinica Universidad De Navarra | Pamplona | Oncologia · Pamplona, Spain
    • Hospital Hm Nou Delfos | Oncologia · Barcelona, Spain
    • Hospital Universitari Vall D Hebron | Oncologia · Barcelona, Spain
    • Hospital Universitario Fundacion Jimenez Diaz | Oncologia · Madrid, Spain
    • Hospital Universitario Virgen De La Victoria | Oncologia · Málaga, Spain
    • Hospital Clinico Universitario De Valencia | Oncologia · Valencia, Spain
    • The Royal Marsden (Surrey) | Oak Foundation Drug Development Unit · Sutton, United Kingdom
    Show 14 removed
    • Centre Hospitalier Universitaire (CHU) de Liege - Domaine Universitaire du Sart Tilman - Medical Oncology · Liège, Belgium
    • Centro di Riferimento Oncologico di Aviano - Oncologia Medica e dei Tumori Immuno-Correlati · Aviano, Italy
    • Fondazione IRCCS Istituto Nazionale dei Tumori - S. C. Oncologia Medica 1 · Milan, Italy
    • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Fase I · Roma, Italy
    • I.F.O. Istituti Fisioterapici Ospitalieri - Sperimentazioni cliniche Fase 1 e Medicina di precisione · Roma, Italy
    • Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia · Rozzano, Italy
    • Universitair Medisch Centrum Groningen (UMCG) - UMC Groningen Comprehensive Cancer Center · Groningen, Netherlands
    • Hospital Hm Nou Delfos | Oncologia · Barcelona, Spain
    • Hospital Universitari Vall D Hebron | Oncologia · Barcelona, Spain
    • Hospital Universitario Fundacion Jimenez Diaz | Oncologia · Madrid, Spain
    • Hospital Universitario Virgen De La Victoria | Oncologia · Málaga, Spain
    • Hospital Clinico Universitario De Valencia | Oncologia · Valencia, Spain
    • Clinica Universidad De Navarra | Pamplona | Oncologia · Pamplona, Spain
    • The Royal Marsden Hospital (Sutton, Surrey) | Oak Foundation Drug Development Unit · Sutton, United Kingdom
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06914128
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 6, 2025
Start date
Mar 21, 2025
Primary completion
Jun 18, 2029 (estimated)
Completion
Jun 18, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Bayer Clinical Trials Contact
Contact
clinical-trials-contact@bayer.com
18888422937

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion